Opinion|Videos|December 3, 2024
Examining FMT for Patients With Recurrent C Difficile infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections.
- Recent data shows FMT's high efficacy in preventing recurrent C. difficile, outperforming standard antibiotic treatments.
The panelist discusses how fecal microbiota transplantation (FMT) involves transferring stool from healthy donors to restore gut microbiota in patients with recurrent Clostridioides difficile infection, though safety concerns include potential pathogen transmission and careful donor screening requirements, while OpenBiome’s standardized frozen FMT preparations have helped advance accessibility but should be used according to current FDA guidance for investigational use.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Describe how FMT works and for which patients this can be used.
- What has recent data shown about the efficacy of FMT in preventing recurrent C difficile?
- What are the safety concerns when using FMT?
- Discuss the recent updates of an investigational FMT therapy from OpenBiome, and how this impacts your clinical decision-making.
Advertisement
Related to this article
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Contributor: Congress Can Bring Mental Health Care to the 21st Century
5